Inebilizumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Inebilizumab
Accession Number
DB12530
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Inebilizumab has been used in trials studying the treatment of Blood Cancer, B-cell Malignancies, Advanced B Cell Malignancies, Chronic Lymphocytic Leukemia (CLL), and Diffuse Large B-Cell Lymphoma (DLBCL).

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
MEDI-551
Categories
UNII
74T7185BMM
CAS number
1299440-37-1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Inebilizumab.
AbituzumabThe risk or severity of adverse effects can be increased when Inebilizumab is combined with Abituzumab.
AbrilumabThe risk or severity of adverse effects can be increased when Inebilizumab is combined with Abrilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Inebilizumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Inebilizumab.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Inebilizumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Inebilizumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Inebilizumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Inebilizumab.
AmatuximabThe risk or severity of adverse effects can be increased when Inebilizumab is combined with Amatuximab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911342
Wikipedia
Inebilizumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic SciencePlasma Cell Myeloma1
1CompletedTreatmentAdvanced B Cell Malignancies / Blood Cancers1
1CompletedTreatmentScleroderma1
1, 2CompletedTreatmentB-Cell Malignancies / Malignancies1
1, 2CompletedTreatmentRelapsed/Refractory Aggressive B-cell Lymphomas1
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL)1
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2TerminatedTreatmentMultiple Myeloma (MM)1
2, 3Active Not RecruitingTreatmentNeuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders / Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders (NMO/NMOSD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 16:44 / Updated on June 04, 2019 07:39